Literature DB >> 27501237

Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM.

Robert Pirker1.   

Abstract

Entities:  

Year:  2016        PMID： 27501237      PMCID： PMC4958816          DOI： 10.21037/jtd.2016.05.54

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

1.  Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature.

Authors:  Kazuyuki Tsujino; Takayasu Kurata; Satomi Yamamoto; Tomoya Kawaguchi; Akihito Kubo; Shunichi Isa; Yoshikazu Hasegawa; Sai-Hong Ignatius Ou; Minoru Takada; Masahiko Ando
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

Review 2.  A tobacco-free world: a call to action to phase out the sale of tobacco products by 2040.

Authors:  Robert Beaglehole; Ruth Bonita; Derek Yach; Judith Mackay; K Srinath Reddy
Journal:  Lancet       Date:  2015-03-14       Impact factor: 79.321

Review 3.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

Authors:  Anne Aupérin; Cecile Le Péchoux; Estelle Rolland; Walter J Curran; Kiyoyuki Furuse; Pierre Fournel; Jose Belderbos; Gerald Clamon; Hakki Cuneyt Ulutin; Rebecca Paulus; Takeharu Yamanaka; Marie-Cecile Bozonnat; Apollonia Uitterhoeve; Xiaofei Wang; Lesley Stewart; Rodrigo Arriagada; Sarah Burdett; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

4.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Authors:  Charles Butts; Mark A Socinski; Paul L Mitchell; Nick Thatcher; Libor Havel; Maciej Krzakowski; Sergiusz Nawrocki; Tudor-Eliade Ciuleanu; Lionel Bosquée; José Manuel Trigo; Alexander Spira; Lise Tremblay; Jan Nyman; Rodryg Ramlau; Gun Wickart-Johansson; Peter Ellis; Oleg Gladkov; José Rodrigues Pereira; Wilfried Ernst Erich Eberhardt; Christoph Helwig; Andreas Schröder; Frances A Shepherd
Journal:  Lancet Oncol       Date:  2013-12-09       Impact factor: 41.316

Review 5.  2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.

Authors:  W E E Eberhardt; D De Ruysscher; W Weder; C Le Péchoux; P De Leyn; H Hoffmann; V Westeel; R Stahel; E Felip; S Peters
Journal:  Ann Oncol       Date:  2015-04-20       Impact factor: 32.976

6.  Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.

Authors:  Gudrun Pohl; Gerhard Krajnik; Reza Malayeri; Rolf-Michael Müller; Walter Klepetko; Franz Eckersberger; Cornelia Schäfer-Prokop; Boris Pokrajac; Susanne Schmeikal; Alfred Maier; Gerhard Ambrosch; Michael Woltsche; Wilma Minar; Robert Pirker
Journal:  Lung Cancer       Date:  2006-08-22       Impact factor: 5.705

7.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Suresh Senan; Anthony Brade; Lu-Hua Wang; Johan Vansteenkiste; Shaker Dakhil; Bonne Biesma; Maite Martinez Aguillo; Joachim Aerts; Ramaswamy Govindan; Belén Rubio-Viqueira; Conrad Lewanski; David Gandara; Hak Choy; Tony Mok; Anwar Hossain; Neill Iscoe; Joseph Treat; Andrew Koustenis; Bélen San Antonio; Nadia Chouaki; Everett Vokes
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

10.  Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.

Authors:  Audrey Mauguen; Jean-Pierre Pignon; Sarah Burdett; Caroline Domerg; David Fisher; Rebecca Paulus; Samithra J Mandrekar; Chandra P Belani; Frances A Shepherd; Tim Eisen; Herbert Pang; Laurence Collette; William T Sause; Suzanne E Dahlberg; Jeffrey Crawford; Mary O'Brien; Steven E Schild; Mahesh Parmar; Jayne F Tierney; Cécile Le Pechoux; Stefan Michiels
Journal:  Lancet Oncol       Date:  2013-05-14       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.